Cytotoxicity and enzyme inhibition studies of polyoxometalates and their chitosan nanoassemblies  by Shah, Hamid Saeed et al.
C
p
H
J
a
b
a
A
R
R
A
A
K
P
C
C
A
C
1
t
(
s
a
h
i
h
a
j
2
(Toxicology Reports 1 (2014) 341–352
Contents lists available at ScienceDirect
Toxicology  Reports
journa l h om epa ge: www.elsev ier .com/ locate / toxrep
ytotoxicity  and  enzyme  inhibition  studies  of
olyoxometalates  and  their  chitosan  nanoassemblies
amid  Saeed  Shaha,  Rami  Al-Oweinib, Ali  Haiderb, Ulrich  Kortzb,
amshed Iqbala,∗
Centre for Advanced Drug Research, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan
School of Engineering and Science, Jacobs University, P.O. Box 750 561, 28725 Bremen, Germany
 r  t  i c  l  e  i  n  f  o
rticle history:
eceived 29 March 2014
eceived  in revised form 1 June 2014
ccepted 1 June 2014
vailable  online 6 June 2014
eywords:
olyoxometalate
hitosan
ytotoxicity
lkaline phosphatase
hitosan-polyoxometalate nanoassemblies
a  b  s  t  r  a  c  t
Polyoxometalates  (POMs)  have  become  very  signiﬁcant  in  biomedical  research  for  their
structural diversity  which  renders  them  highly  active  against  bacterial,  viral  and  can-
cer diseases.  In this  study  three  different  POMs  were  synthesized  and  nanoassemblies
were  made  with  chitosan  (CTS),  a natural  biodegradable  polymer  with  excellent  drug car-
rier properties.  The  compounds  were  tested  on  two isoenzymes  of alkaline  phosphatases
including  tissue  speciﬁc  calf  intestine  alkaline  phosphatase  (CIAP)  and tissue  non-speciﬁc
alkaline  phosphatase  (TNAP).  Compound  [TeW6O24]6− (TeW6) showed  the  highest  activity
(45.4  ±  11.3  nM)  among  tested  compounds  against  TNAP.  Similarly,  chitosan-[TeW6O24]6−
(CTS-TeW6)  was  proved  to  be  a  potent  inhibitor  of CIAP  with  Ki value  of 22  ±  7  nM.  A  com-
parative  study  was  made  to evaluate  their  cytotoxic  potential  against  HeLa  cells.  Among
all tested  compounds,  Chitosan-[NaP5W30O110]14− (CTS-P5W30) has  showed  higher  per-
cent  cytotoxicity  (88 ±  10%)  at 10  M when  compared  with  the  standard  anticancer  drug
vincristine  (72  ±  7%).  The  study  revealed  that selected  POMs  proved  excellent  anticancer
potential  and were  equally  effective  against  alkaline  phosphatase  enzyme,  an  increased
level  of  which  may  indicate  cancer  metastasis.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe CC  B
. Introduction
Polyoxometalates (POMs) are discrete metal oxide clus-
ers  of early transition metal ions in high oxidation states
e.g.  W6+, Mo6+, V5+), which exhibit exceptional diver-
ity in shape, size, and structural properties [1–4]. POMs
re  classiﬁed in two distinct families, namely, iso- and
eteropolyanions [5,6]. The number of heteropolyanions
s larger than that of isopolyanions, thus making them
ighly interesting compounds for several applications
nd ﬁelds of study. Such attributes, in addition to their
∗ Corresponding author. Tel.: +92 992 383591 96; fax: +92 992 383441.
E-mail addresses: drjamshed@ciit.net.pk, jamshediqb@gmail.com,
amshed.iqbal@uni-bonn.de (J. Iqbal).
http://dx.doi.org/10.1016/j.toxrep.2014.06.001
214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
http://creativecommons.org/licenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
solubility and stability at physiological pH, render them
very  attractive in medicine [6–10]. Another promising fea-
ture  of POMs is that they can easily interact and bind
to the target macromolecule because of their diversity
in size, shape, polarity, surface charge distribution, and
redox  potential which improves their bonding properties
[11].
Bioinorganic metal complexes have been studied exten-
sively  for targeted anticancer drug therapy [12–15]. The
most  promising metal-based anticancer drug is cisplatin,
which is effective against lymphomas, head, neck, bladder
and  ovarian cancers [16–18]. POMs have excellent poten-
tial  to treat various types of cancers including pancreatic
cancer [19], leukemia [20], hepatocellular carcinoma [21],
colon  carcinoma [22], ovarian cancer [23], gastric can-
cer  [24], among others. Moreover, POMs were reported to
is is an open access article under the CC BY-NC-ND license
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stimulate insulin secretion and regenerate pancreatic beta
cell  function in rodents [25–31]. POMs are also very effec-
tive  in treating bacterial [32–34] and viral [35–38] diseases.
A  very recent study shows the ability of POMs, speciﬁ-
cally [TeW6O24]6−, to act as a co-crystallization agent in
the  isolation and crystallization of the latent isoform PPO4
mushroom (Agaricus bisporus) tyrosinase protein which
helps  in the catalytic activity of phenols oxidation to
quinones which in turn are responsible for the generation
of  melanins by polymerization [39].
Encapsulation of POMs into a biodegradable polymer
has been studied previously, which enhances its stability
at  physiological pH, hence improving antiviral, antibacte-
rial  and anticancer properties [33,40–43]. Chitosan (CTS)
is  a natural, biodegradable polymer that has become one
of  the most widely studied biomaterial so far. Chitosan is
obtained  by de-acetylation of chitin, an essential polysac-
charide, which is found in the exoskeleton of shrimps
and crab shells [44,45]. Chitosan can be effectively used
in  extended release drug delivery system because it is
degraded in the human body by ubiquitous enzymes chi-
tosanase  and lysozyme which aid in releasing the drug
in  a controlled and precise manner [46,47]. A combi-
nation of chitosan with inorganic, bioactive compounds
suggests high potential for the development of new drug
molecules with low toxicity, high stability and effective
bio-distribution [48–52].
Ectonucleotidases represent a membrane-bound
enzymes family, which mainly includes ecto-nucleoside
triphosphate diphosphohydrolases (E-NTPDases) and
alkaline phosphatases that are involved in nucleotide
metabolism. Inhibition of these enzymes may  increase
the immune response and helps in combating cancer,
auto-immune diseases as well as bacterial and viral
infections [53]. POMs have been identiﬁed as potent
and selective inhibitors of NTPDases [54] and alkaline
phosphatases [55,56]. Alkaline phosphatase level usually
rises  in colon, breast, lung, thyroid and prostate cancer
when it metastasizes to bone and liver [57–62].
In the present study, POMs and their respective CTS
associated nanoassemblies were synthesized, structurally
characterized and evaluated for inhibition activity against
alkaline phosphatase isoenzymes (TNAP and CIAP). In
addition, a comparative in vitro cytotoxicity analysis of
synthesized compounds with standard anticancer drug
Fig. 1. Structural representations of the POMs. (a) [NaP5W30O110]orts 1 (2014) 341–352
vincristine (VCN) was carried out on human cervical ade-
nocarcinoma (HeLa) cells.
2.  Materials and methods
All  chemicals used for the synthesis of the POMs were
purchased commercially and used as received without fur-
ther  puriﬁcation. Chitosan (YC-100) (M ∼10,000 g/mol),
tissue non-speciﬁc alkaline phosphatase enzyme (TNAP),
L-phenylalanine, levamisole, Tris–HCl, Tris base, MgCl2,
ZnCl2, RPMI-1640, fetal bovine serum (FBS), penicillin
and streptomycin were purchased from Sigma–Aldrich,
Steinheim, Germany. Tissue speciﬁc alkaline phosphatase
enzyme extracted from calf intestine (CIAP) was obtained
from Calbiochem, Germany. Human cervical adenocarci-
noma cell line (HeLa) was purchased from ATCC (ATCC
CRL-5802) and vero cell line was  acquired from RIKEN Bio
Resource  Center, Japan.
POMs  were synthesized and encapsulated with CTS to
form  CTS-POMs nanoassemblies. The synthesis and char-
acterization of these materials are given below.
2.1. Synthesis of (NH4)14[NaP5W30O110]·31H2O
(NH4)14[NaP5W30O110]·31H2O (NH4-P5W30) was syn-
thesized according to a previously described method [63],
and  characterized by FT-IR (Fig. 3b) and 31P NMR  spec-
troscopy. 31P NMR  spectrum (Fig. 2a) obtained shows
the characteristic signal at −9.4 ppm The structure of the
polyanion is shown in Fig. 1a.
2.2. Synthesis of chitosan-[NaP5W30O110]14−
nanoassembly
Chitosan-[NaP5W30O110]14− (CTS-P5W30) nanoassem-
bly was synthesized by dissolving 0.50 g (0.71 mM)  of
chitosan (CTS) in 70 mL  of distilled water. The resul-
tant solution was ﬁltered (solution I). Similarly, 1.24 g
(21.38  mM)  of [NaP5W30O110]14− was dissolved in 30 mL
of H2O and the obtained solution was ﬁltered (solution
II). Solution II was  added dropwise to solution I, and
then gel-like precipitates were formed and separated from
the  solution by means of ﬁltration, washed and air-dried.
The obtained product was characterized by FT-IR spec-
troscopy (Fig. 3a), where the appearance of 936, 910, 795,
14− (P5W30), (b) [V10O28]6− (V10), (c) [TeW6O24]6− (TeW6).
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Fig. 2. A representative NMR  spectra of POMs. (a) 31P NMR  spec-
trum of (NH4)14[NaP5W30O110]·31H2O ((NH4)14-P5W30) in H2O/D2O
(ı = −9.4 ppm); (b) 51V NMR  spectrum of Na6[V10O28]·18H2O (Na6-V10) in
H2O/D2O (ı = −423.3 V10A, −498.8 V10B, −514.4 V10C and −576.5 V1 ppm);
(c) 183W NMR  spectrum of Na6[TeW6O24]·22H2O (Na6-TeW6) in H2O/D2O
(ı = −115.6 ppm).orts 1 (2014) 341–352 343
737 and 570 cm−1 bands conﬁrmed the formation of the
nanoassembly.
2.3.  Synthesis of Na6[V10O28]·18H2O
Compound Na6V10O28·16H2O (Na6-V10) (Fig. 1b) was
prepared by adapting previously described methods
[64,65]. Typically, NaVO3 (3 g, 24.6 mmol) is dissolved in
100  mL  water and HCl (4 M)  was used to reduce the pH
to  4.8. The solution was ﬁltered and HCl was added to
maintain the pH at 4.5. The bulk sodium salt of the polyan-
ion  was obtained by the addition of 200 mL  ethanol (95%,
v/v),  leading to an orange color precipitates, which were
removed by ﬁltration and air-dried. The product was char-
acterized by FT-IR (Fig. 4b) and 51V NMR  spectroscopy,
where V1 corresponds to the monomeric (VO43−) vanadate
species whereas V10A, V10B and V10C signals correspond to
the V(3), V(1) and V(2) vanadium atoms in the decameric
vanadate species (V10O286−). 51V NMR  spectrum obtained
(Fig. 2b) shows the characteristic signal of decameric (V10A
at  −423.3 ppm; V10B at −498.8 ppm; V10C at −514.4 ppm)
and monomeric species (V1 at −576.5 ppm). The structure
of  polyanion is shown in Fig. 1b.
2.4. Synthesis of chitosan-[V10O28]6− nanoassembly
Synthesis of the chitosan-[V10O28]6− (CTS-V10)
nanoassembly was  carried out by dissolving 0.50 g
(0.71  mM)  of chitosan (CTS) in 70 mL  of distilled water and
ﬁltered  (solution I). A 0.43 g (10.1 mM)  of [V10O28]6− was
dissolved in 30 mL  of distilled water and ﬁltered (solution
II).  The solution (II) was  added dropwise to solution (I). The
gel-like  precipitates were formed and separated from the
solution  by means of ﬁltration, washed and air-dried. The
obtained  product was characterized by FT-IR spectroscopy
(see Fig. 4a), where the appearance of 1074, 950, 821,
and  744 cm−1 bands conﬁrmed the formation of the
nanoassembly.
2.5. Synthesis of Na6[TeW6O24]·22H2O
Na6[TeW6O24]·22H2O (Na6-TeW6) (Fig. 1c) was syn-
thesized by previously reported method with some
modiﬁcations [66] Brieﬂy, A mixture of Na2WO4·2H2O
(5.0  g, 15.2 mmol) and Te(OH)6 (0.6 g, 2.6 mmol) were dis-
solved  in 100 mL  of water. The pH was adjusted to 5.0
with  HCl (1 M)  followed by heating at 110 ◦C until about
one  fourth of the solvent has been evaporated. The solu-
tion  was allowed to cool and ﬁltered. Slow evaporation
of the ﬁltrate at room temperature for one week led to
the  formation of colorless crystals, which were collected
by  ﬁltration and air-dried. The product was  characterized
by FT-IR (Fig. 5b) and 183W NMR  spectroscopy. 183W NMR
spectrum obtained (Fig. 2c) shows the characteristic signal
at  115.6 ppm. The structure of polyanion is shown in Fig. 1c.2.6.  Synthesis of chitosan-[TeW6O24]6− nanoassembly
Chitosan-[TeW6O24]6− (CTS-TeW6) nanoassembly was
synthesized by dissolving 0.50 g (0.71 mM)  of CTS in 70 mL
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TS (blueFig. 3. The FT-IR spectra of (a) CTS-P5W30, (b) P5W30 (red line), and (c) C
the  reader is referred to the web version of the article.)
distilled water. The resultant solution was ﬁltered (solution
I).  Similarly, 0.64 g (9.9 mM)  of [TeW6O24]6− was dissolved
in 30 mL  H2O and the product was ﬁltered (solution II).
Solution (II) was added dropwise into solution (I) leading
to  the formation of gel-like precipitates which were sep-
arated  by ﬁltration and washed several times with water
and  air-dried. The obtained product was characterized by
FT-IR  spectroscopy (Fig. 5a), where the appearance of 948,
903,  679, 617 and 556 cm−1 bands conﬁrmed the formation
of  the nanoassembly.
2.7.  Zeta potential and particle size measurementThe CTS-POMs nanoassemblies were characterized by
zeta  potential to check their stability in colloidal sus-
pension. Furthermore the particle size of the selected
compound CTS-P5W30 was also determined. line). (For interpretation of the references to color in this ﬁgure legend,
2.8. Enzyme inhibition studies against alkaline
phosphatases
Each compound was tested on TNAP and CIAP enzymes.
Each enzyme was  diluted in a buffer having pH 9.5 prepared
from  50 mM Tris–HCl, 5 mM MgCl2, 0.1 mM ZnCl2 and
50% glycerol. A 0.5 mM enzyme substrate p-nitrophenyl
phosphate (p-NPP) solution was  also prepared in assay
buffer (pH 9.5) comprised of 50 mM Tris–HCl, 5 mM MgCl2,
0.1  mM ZnCl2 without glycerol.
The initial screening of test compounds was done at
0.1  mM concentration by using a previously described
spectrophotometric method [67]. The standard inhibitors
were  employed for initial screening to compare and
evaluate the inhibition capacity of test compounds. Lev-
amisole  was  used as standard inhibitor of TNAP [68] while
l-phenylalanine was  used for CIAP [69]. Brieﬂy, the com-
pounds  which showed ≥50% inhibition were selected and
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Fig. 4. The FT-IR spectra of (a) CTS-V10, (b) V10 (red line), and (c) CTS (blue line). (For interpretation of the references to color in this ﬁgure legend, the
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urther tested to determine dose–response curve of each
nhibitor. Generally, each compound was pre-incubated
ith 10 L of enzyme and 70 L of assay buffer at 37 ◦C
or  10 min  A 10 L of p-NPP was added and the mix-
ure was again incubated for 30 minutes The product
p-nitrophenolate) formed was measured on ELISA plate
eader  (Bio-TekELx 800TM, Instruments, Inc. USA) at wave-
ength of 405 nm.  The experiments were done in triplicate.
he  respective K value of each inhibitor was calculatedi
y using Prism 5.0 (GraphPad Software, San Diego, CA,
SA).2.9.  Cell lines and cell cultures
HeLa  cells and vero cells were cultured in a medium
containing RPMI-1640 supplemented with l-glutamine
(2 mM),  penicillin (100 U mL−1) and streptomycin
(100 g mL−1) accompanied with 10% FBS and stored
in an incubator supplied with 5% CO2 at a constant tem-
perature of 37 ◦C. When both adherent cell lines were
conﬂuent the cells were cultivated in 96-well plates
at  a seeding density of 104 cells in 100 L to conduct
cytotoxicity assays.
346 H.S. Shah et al. / Toxicology Reports 1 (2014) 341–352
 (blue linFig. 5. The FT-IR spectra of (a) CTS-TeW6, (b) TeW6 (red line), and (c) CTS
reader  is referred to the web version of the article.)
2.10. Cytotoxicity analysis by sulforhodamine B (SRB)
assay
A  previously described colorimetric cytotoxicity assay
was  adopted which measures cellular protein content of
cells  [70]. Concisely, Hela cells and vero cells were seeded
in  96 well plates for 24 h. Different concentrations of test
compounds (10, 1, 0.1 M)  were made and inoculated in
test  wells of 96 well plates and incubated for up to 48 h.
Likewise, the control and blank wells were also prepared
containing VCN and culture medium respectively. After
incubation, the cells were ﬁxed with 50 L of 50% ice cold
TCA  solution for 1 h. The plates were washed 5 times with
PBS  and air dried. The ﬁxed cells were further treated with
0.4%  (w/v) sulforhodamine B dye prepared in 1% acetic
acid  solution and left at room temperature for 30 min
The  plates were rinsed with 1% acetic acid solution and
allowed to dry. In order to solubilize the dye, a 10 mMe). (For interpretation of the references to color in this ﬁgure legend, the
Tris  base solution was  added and left for 10 min  at room
temperature. The absorbance was  measured at 490 nm
subtracting the background measurement at 630 nm.
3. Results and discussion
3.1.  Synthesis of POMs and their chitosan based
nanoassemblies
POMs and their chitosan linked nanoassemblies were
synthesized and characterized by NMR, and FT-IR. The
results are presented in Figs. 1–5.
3.2. Characterization of chitosan-POMs nanoassembliesThe successful formations of chitosan-POM nanoassem-
blies were conﬁrmed by the appearance of characteristic
bands in the region of 1000–500 cm−1 in the respective
H.S. Shah et al. / Toxicology Rep
Table 1
Zeta  potential measurement of POMs and their chitosan nanoassemblies.
Code Particle size ± SEMa
(nm)
Zeta potential ± SEMa
(mV)
CTS-P5W30 100 −44.56 ± 2.48
F
s
w
w
T
p
F
C
oCTS-V10 – −23.83 ± 1.09
CTS-TeW6 – −37.06 ±  2.55
a SEM of 3 experiments performed in triplicate.
T-IR spectra as compare to that of simple POM FT-IR
pectra. The stability of chitosan-POM nanoassemblies
as determined by zeta potential measurement which
as  found in the range of −23 to −45 mV  (see Table 1).
he maximum stability was given by CTS-P5W30 with zeta
otential of −44.56 ± 2.48 mV  (see Fig. 6b) while particle
ig. 6. A representation of particle size measurement and zeta potential of
TS-POMs, (a) TEM image of CTS-P5W30 (b) zeta potential measurement
f CTS-POMs nanoassemblies.orts 1 (2014) 341–352 347
size of CTS-P5W30 was  also determined with transmission
electron microscopy (TEM) that was  100 nM (see Fig. 6a). A
possible  reason for negative zeta potential is the presence
of  a highly negative charge on the polyanions [71].
3.3. Inhibition studies on alkaline phosphatases
An elevated level of the alkaline phosphatase enzyme
has been studied as a non-speciﬁc tumor marker associated
with  certain abnormalities in physiological functions of
human  body [72,73]. In recent years, the biological signiﬁ-
cance  of POMs has become apparent and many studies have
been  reported in this context [21,54,74]. The present study
was  presented on the synthesis and evaluation of POMs and
their  CTS associated nanoassemblies, which were found
potent inhibitor of alkaline phosphatases with Ki values in
nano  molar range
POMs  and CTS-POMs nanoassemblies were tested
against two  different isoenzymes of alkaline phosphatase,
i.e. CIAP and TNAP. The test compounds were initially
screened at 0.1 mM end concentration, which showed more
than  70% inhibition on both isoenzymes. In order to ﬁnd Ki
value, a 3-fold serial dilution of each compound was made
and  Ki value was determined in nano molar range. Among
CTS-POMs nanoassemblies the highest inhibition against
CIAP  was  given by CTS-TeW6, with a Ki value of 22 ± 7 nM,
while  CTS-P5W30 and CTS-V10 also showed a decent inhibi-
tion with 31.1 ± 7.8 nM and 509 ± 17 nM,  respectively. The
TeW6 was  the most potent TNAP inhibitor among all tested
compounds with a Ki value of 45.4 ± 11.3 nM.  A possible
reason for higher selectivity and inhibition potential of CTS-
TeW6 and TeW6 may  be due to the presence of tellurium
metal, which has been proved previously in reducing ALP
levels  in diabetic rats [75]. Dose–response curves of were
made  (Fig. 7) and presented in a comparative manner to
evaluate  the activity against ALP isoenzymes (see Table 2).
3.4.  Anticancer activity studies
3.4.1. Cytotoxicity assay
POMs  and their chitosan-encapsulated nanoassemblies
were tested as anticancer agents on HeLa cells. The
test compounds were prepared in different concentration
ranges of 10, 1 and 0.1 M.  All test compounds showed
good cytotoxicity against HeLa cells, even at the lowest con-
centration  of 0.1 M with minimum toxicity against vero
cells  (see Table 3). The maximum cytotoxicity against HeLa
cells  was observed with the compound CTS-P5W30 having
percent inhibition of 88 ± 10 (see Fig. 8), that may  be due
to  the higher number of phosphorous (P) and tungsten (W)
atoms  [55].
A  difference of cytotoxicity behavior was observed
between P5W30, TeW6, CTS-P5W30 and CTS-TeW6, which
support the idea that the encapsulation of POMs into a
biopolymer may  render polyanion more target oriented,
with minimal adverse effects [76]. The vanadium (V)
containing compounds have previously been reported
as  good anticancer and antidiabetic agents [77,78]. Here
we  have synthesized compounds V10 and CTS-V10 which
also showed promising cytotoxicity behavior 66 ± 15%
and  81 ± 9% respectively. The compound CTS-TeW6 has
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Fig. 7. The potential activities of POMs and their chitosan based nanoassemblies on CIAP (blue line) and TNAP (black line) isoenzymes. (For interpretation
of  the references to color in this ﬁgure legend, the reader is referred to the web  version of the article.)
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Fig. 8. A graphical representation of multiple comparisons of anticancer activities between POMs, their chitosan based nanoassemblies and VCN.
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Table 2
Activities of POMs and CTS based nanoassemblies against CIAP and TNAP.
No. Code Molecular formula/structure Ki (nM) ± SEMa
CIAPb TNAPc
1 P5W30 (NH4)14[NaP5W30O110]·31H2O 921 ± 6 1112 ± 36
2  CTS-P5W30 Chitosan-[NaP5W30O110]14− 31.1 ± 7.8 3179 ± 84
3  V10 Na6[V10O28]·18H2O 79.1 ± 2.3 169 ± 21
4  CTS-V10 Chitosan-[V10O28]6− 509 ± 17 308 ± 63
5  TeW6 Na6[TeW6O24]·22H2O 520 ± 13 45.4  ± 11.3
6  CTS-TeW6 Chitosan-[TeW6O24]6− 22 ± 7 1921  ± 54
7  l-phenylalanine OH
NH2
O
75% –
8  Levamisole
N
NS
– 71%
a SEM = standard error of mean of 3 experiments.
b CIAP (calf intestinal alkaline phosphatase).
c TNAP (tissue non-speciﬁc alkaline phosphatase).
Table 3
The  cytotoxicity comparison of vincristine, POMs and their chitosan based nanoassemblies on Hela and vero cells.
Codes Percent
inhibition ± SEMa at
10 M on vero cells
Percent
inhibition  ± SEM at
10  M on Hela cells
Percent
inhibition  ± SEM at
1  M on Hela cells
Percent
inhibition  ± SEM at
0.1  M on Hela cells
VCNb 10 ± 4 72 ± 7 – –
P5W30 15 ± 6 74 ± 10 62 ± 13 54 ± 6
CTS-P5W30 12 ± 5 88  ± 10 78  ± 15 65 ± 9
V10 16 ± 3 66 ± 15 57 ± 13 49 ± 11
CTS-V10 11 ± 2 81 ± 9 73 ± 9 58 ± 11
TeW6 16 ± 8 69 ± 10 62 ± 10 53 ± 12
.CTS-TeW6 11 ± 6 84 ± 10 
a SEM Standard error of mean of 3 experiments performed in triplicate
b VCN (vincristine).
anticancer activity of 84 ± 10% against HeLa cells which
may  be due to the presence of tellurium atom, which was
previously reported as anticancer agent [79,80].
4. Conclusions
We  can state that much insight has already been gained
on  the bio-activity of POMs. Here we have adopted a
previously used technique to synthesize and encapsulate
three different POMs; P5W30, V10 and TeW6 with CTS to
enhance drug carrier properties. The anticancer poten-
tial  of these synthesized compounds were studied against
alkaline phosphatases and Hela cells in a dose-dependent
manner to explore their capacity in minimizing side effects
through  dose adjustment. The anticancer activity of these
nanoassemblies, in particular, CTS-P5W30 allows for new
strategies of treating cancer. Among the tested compounds,
especially CTS-POMs nanoassemblies showed minimum
toxicity against normal cells. Our results suggest that the
CTS-POMs nanoassemblies have a high potential of treating
cancer  and its metastasis.Transparency document
The  Transparency document associated with this article
can  be found in the online version.
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